Anti-CXCR3 / GPR9 / CD183

Catalog No.A2706 Purity:≥99%

Anti-CXCR3 / GPR9 / CD183 is a monoclonal antibody binds to Chemokine (C-X-C motif) receptor 3 (CXCR3, also known as G protein-coupled receptor 9 (GPR9)) . It has the potentially to be used in the treatment of diabetes mellitus type I (T1D). MW: 146.38 KD.

Purity & Quality Control

≥99

Choose Selective CXCR Inhibitors

Name	Citation	CXCR1	CXCR2	CXCR4	CXCR3	Others
WZ811	20			++++
Mavorixafor	0			+
AMG 487	1				+++
Motixafortide (BL-8040)	0			++++		cyclin-D1,MCL-1,Bcl-2
Navarixin (SCH-527123)	4	++	+++
MSX-122	1			+++
LY2510924	2			++++
Reparixin (Repertaxin)	17	++++	+			CXCL8
SB225002	76		++
SB 265610		✔
Balixafortide (POL6326)			✔
SX-682	✔
MSX-130			✔
MSX-127			✔
AZD5069		✔
Danirixin (GSK1325756)		✔			CXCL8
LIT-927			✔		CXCL12
AMD3465 hexahydrobromide			✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Anti-CXCR3 / GPR9 / CD183 is a monoclonal antibody binds to Chemokine (C-X-C motif) receptor 3 (CXCR3, also known as G protein-coupled receptor 9 (GPR9)) . It has the potentially to be used in the treatment of diabetes mellitus type I (T1D). MW: 146.38 KD.

References
[1] Yound M, et al. WO2013109974A2.

References

[1] Yound M, et al. WO2013109974A2.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

Molecular Weight	146.38
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.